Opthea Announces Leadership Change as Phase 3 Trials Near

Opthea Limited (AU:OPT) has released an update.

Opthea Limited announced that Dr. Megan Baldwin will retire from its Board but will remain as Chief Innovation Officer, focusing on advancing the company’s innovation strategy. As Opthea gears up for pivotal Phase 3 data readouts for its lead product, sozinibercept, Dr. Baldwin’s continued leadership is seen as crucial. The company is also in the process of identifying a new board director to fill the upcoming vacancy.

For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.